A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma.
Kakiuchi-Kiyota S, Ross T, Wallweber HA, Kiefer JR, Schutten MM, Adedeji AO, Cai H, Hendricks R, Cohen S, Myneni S, Liu L, Fullerton A, Corr N, Yu L, de Almeida Nagata D, Zhong S, Leong SR, Li J, Nakamura R, Sumiyoshi T, Li J, Ovacik AM, Zheng B, Dillon M, Spiess C, Wingert S, Rajkovic E, Ellwanger K, Reusch U, Polson AG.
Kakiuchi-Kiyota S, et al. Among authors: ellwanger k.
Leukemia. 2022 Apr;36(4):1006-1014. doi: 10.1038/s41375-021-01478-w. Epub 2022 Jan 10.
Leukemia. 2022.
PMID: 35001074